Recent Updates
Recently added Catalysts
SPRB Positive Sentiment

Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting

Thursday, October 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Spruce Biosciences has announced the presentation of data from Study 250-902 at the 55th Child Neurology Society Annual Meeting. This study focuses on understanding the progression of MPS IIIB in pediatric patients. The findings aim to shed light on this severe condition and support future therapeutic developments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation of significant natural history data.
  • Focus on addressing unmet medical needs in neurological disorders.
  • Collaboration with multiple centers enhances study credibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
6.4%
average across 4 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
SPR001
Phase 2 · Congenital Adrenal Hyperplasia

Full Press Release Details

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data from Study 250-902 (NCT03227042), a prospective, multicenter, multinational, noninterventional, longitudinal natural history study designed to characterize disease progression in pediatric participants with severe, non-attenua

Frequently Asked Questions

What is Study 250-902 about?

Study 250-902 is a longitudinal study aimed at characterizing disease progression in pediatric patients with MPS IIIB.

Where was the data presented?

The data was presented at the 55th Child Neurology Society Annual Meeting.

What is the focus of Spruce Biosciences?

Spruce Biosciences focuses on developing therapies for neurological disorders with significant unmet medical needs.

What type of study is Study 250-902?

It is a prospective, multicenter, multinational, noninterventional, longitudinal study.

ShareAdd on Google
Tags: SPRB Spruce Biosciences MPS IIIB neurological disorders Study 250-902 Child Neurology Society
Last updated: Oct 8, 2026

Biotech snapshot

Cash runway
$96M liquidity · $7M/mo burn
~11 mo
Medium dilution risk
Lead asset
SPR001Phase 2
Congenital Adrenal Hyperplasia →

Catalyst track record

+41%
best trade around SPRB's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SPRB.

See every catalyst's timing & PoA →